Cover Image
Market Research Report

Inhaled Drug Delivery to 2022

Published by Greystone Research Associates Product code 228360
Published Content info
Delivery time: 1-2 business days
Back to Top
Inhaled Drug Delivery to 2022
Published: March 16, 2015 Content info:

The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. Systemic delivery continues to represent an area of significant opportunity. Products and product candidates in this category include inhaled drugs for the treatment of such diverse conditions as pulmonary arterial hypertension, neurological disorders, hereditary diseases and pain management.

What You Will Learn

  • Which therapeutic drugs are delivered via aerosol inhalers, dry powder inhalation and nebulizers for upper respiratory conditions? For systemic delivery?
  • What are the inhalable drugs currently in development, their formulation and device strategies, and targeted indication(s) and what are market prospects?
  • What are the key inhalation device technologies for commercial and development-stage devices, and what are the product technology issues and related market factors?
  • What are the current market dynamics of inhaled drug targeted disease segments, and what are the growth prospects and market potential for inhaled therapeutic drugs?
  • What is the current market share for inhaled drugs by product? By supplier? What will it be in seven years?
  • Who are the Inhaled drug product market participants, their products, market strategies, product development activity, and partners?
Table of Contents

Table of Contents

  • Executive Summary
  • The Orally Inhaled Drug Delivery Market
  • Therapeutic Targets
  • Upper Respiratory
  • Systemic Inhaled Delivery
  • Demand Drivers
  • Risk Factors
  • Competing Technologies
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Inhalation Technology & Product Development Factors
  • Formulation Factors
  • Drug Formulations
  • Formulation Technologies
  • Excipients and Release Profiles
  • Inhalation Device Design Factors
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Inhaler Performance Factors
  • Bioavailability
  • Dose Reproducibility
  • Active Compound Stability
  • Testing and Packaging
  • Inhalation Devices - Product & Device Assessments
  • Dry Powder inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Inhaled Drugs - Therapeutic Segment Analysis & Forecasts
  • Upper Respiratory Indications
  • Asthma
  • COPD
  • Systemic Drug Delivery
  • Bioterror
  • Cardiovascular Medicine
  • Pulmonary Hypertension
  • Diabetes
  • Hereditary Diseases
  • Cystic Fibrosis
  • Immunology
  • Infectious Diseases
  • Osteoporosis
  • Neurology
  • Oncology
  • Market Factors
  • Regulatory Issues
  • Patient Compliance
  • Healthcare Economics
  • Connected Devices
  • Market Sector Company Profiles
Back to Top